+++
title = "LabConnect Appoints Bill Finger as Senior Vice President to Enhance Global Strategic Services"
date = "2025-09-18T18:01:10Z"
draft = false
summary = "LabConnect strengthens its leadership team with the appointment of Bill Finger, bringing over 25 years of diagnostics and clinical research expertise to drive innovation in complex study support for immuno-oncology, cell and gene therapies, and rare diseases."
description = "LabConnect appoints Bill Finger as SVP of Global Strategic Services, bringing 25+ years of diagnostics experience to enhance central laboratory services for complex clinical trials."
source_link = "https://www.citybiz.co/article/747303/labconnect-names-bill-finger-as-svp-of-global-strategic-services/"
enclosure = "https://cdn.newsramp.app/citybiz/newsimage/c73ff9d2bc03b5b84504cfef0aa76ea8.jpg"
article_id = 213325
feed_item_id = 20914
qrcode = "https://cdn.newsramp.app/citybiz/qrcode/259/18/dualogRU.webp"
source = "citybiz"
+++

<p>LabConnect has appointed Bill Finger as Senior Vice President of Global Strategic Services, effective September 10, 2025. Finger brings more than 25 years of diagnostics and clinical research experience to the role, with deep expertise in the global laboratory and pharmacy industry. As a senior executive, Finger is recognized as an innovative thinker with proven ability to develop strategy, drive execution, and advance organizational performance while maintaining focus on operational excellence.</p><p>Finger's most recent position was Vice President and General Manager of Pharma Services with Quest Diagnostics. His previous roles include Chief Operating Officer for Interpace Pharma Solutions, Executive Vice President of Precision Medicine and Pharma for Cancer Genetics, and leadership positions in scientific affairs and biorepository with LabCorp. In his new capacity, Finger will lead LabConnect's Scientific Services, Consulting Services, Data Management, and Functional Service Provider teams.</p><p>This strategic appointment comes as the company continues to expand its services for analytically and logistically complex studies including immuno-oncology, cell and gene therapies, and rare and orphan diseases. LabConnect CEO Wes Wheeler emphasized the significance of this appointment, stating that Finger's leadership in diagnostic and clinical research represents a tremendous asset to the organization. Wheeler noted that Finger's experience will help ensure the company continues to anticipate client needs, deliver innovative solutions, and reinforce its commitment to operational excellence for clients worldwide.</p><p>The appointment reflects the growing importance of specialized laboratory services in supporting advanced clinical research, particularly in emerging therapeutic areas that require sophisticated testing capabilities and global coordination. LabConnect's unique combination of technology, laboratory resources, and specialized testing expertise positions the company as a critical partner for drug development companies navigating complex research requirements. This move signals LabConnect's commitment to strengthening its leadership team with seasoned industry professionals who can drive innovation in the rapidly evolving clinical research landscape.</p>